Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
05/27/20 Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
05/20/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
05/15/20 Statement from Alkermes on Response to COVID-19
05/14/20 Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
05/11/20 Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
05/06/20 Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
05/04/20 Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
04/29/20 Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
04/22/20 Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results
04/22/20 Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
03/04/20 Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
02/24/20 Alkermes Response to Media Coverage of the Company and VIVITROL
02/24/20 Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
02/19/20 Alkermes to Present at the 9th Annual SVB Leerink Global Healthcare Conference
02/13/20 Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
02/06/20 Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
01/28/20 Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
01/08/20 Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference